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Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that
impairs motor neuron function, leading to severe muscular atrophy. The non-cell
autonomous and heterogeneous nature of the disease has so far hindered attempts
to define ALS etiology, leaving the disease incurable and without effective treat-
ments. Recent studies have focused on the pathologic role of intercellular commu-
nication between nerve cells to further our understanding of ALS pathophysiology.
In this chapter, we summarize recent works investigating the role of extracellular
vesicles (EVs) as a means of cellular crosstalk for ALS disease propagation, diagno-
sis, and treatment. There is growing evidence that EVs secreted by the majority of
mammalian cells serve as effective biomolecule carriers to modulate recipient cell
behavior. This underscores the need to understand the EV-mediated interplay that
occurs within irreversibly degenerating nervous tissue in ALS patients. Addition-
ally, we highlight current gaps in EV-ALS research, especially in terms of the
pathologic role and responsibilities of specific EV cargos in diseased cells, specificity
issues associated with the use of EVs in ALS diagnosis, and the efficacy of EV-
mediated treatments for the restoration of diseased neuromuscular tissue. Finally,
we provide suggestions for future EV-ALS research to better understand, diagnose,
and cure this inveterate disease.
Keywords: ALS, extracellular vesicle, exosome, propagation, biomarker,
therapeutic agent
1. Introduction
Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is
a heterogeneous neurodegenerative disease that primarily impairs both upper and
lower motor neurons [1, 2]. 5000 people in the United States are diagnosed with
ALS each year, mostly between the ages of 40 and 70. The irreversibly progressive
nature of ALS leads to the death of most patients within 2–5 years of diagnosis,
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typically due to respiratory failure [1, 3]. In most patients, the cause of ALS is
unknown. Only 10% of patients have a familial history of ALS, caused by specific
mutations in their genomes, while 90% are exhibit sporadic ALS due to unknown
causal factors [1, 4, 5]. The lack of understanding concerning ALS disease mecha-
nisms has led to the development of very few FDA approved drugs. To date, those
drugs that have progressed to the US market merely slow down disease progression
by a few months and do little to restore patient’s neuromuscular function [6]. As
progressive degeneration and the non-cell autonomous nature of ALS are known to
be major reasons for this stalemate, the aim of much current ALS research is
focused on understanding the diverse interplay between neurons and non-neuronal
components in neuromuscular tissue. Among the non-neuronal components, glial
cells and their crosstalk with neurons have been major targets of study regarding
symptomatic development and progression in ALS [7–10]. Accordingly, research
into a myriad of proteins and RNAs known to be transmissible between neurons
and glial cells has been gaining interest in recent years. It is already well-established
that such agents can act as molecular ‘messengers’ to alter the behavior of nearby
cells in ALS, but the detailed mechanisms that underpin specific cargo selection,
initiation of transport, and subsequent activation of the internalized biomolecules
are not fully understood.
Extracellular vesicles (EVs) are lipid bi-layered particles, less than 2 μm in size,
secreted by the majority of mammalian cells, including nerve cells, to mediate
diverse paracrine signaling pathways [11–13]. These vesicles are typically classified
into three categories: microvesicles, apoptotic bodies, and exosomes [14].
Microvesicles and apoptotic bodies are normally 0.1–2 μm in size and bud directly
from the plasma membrane. Exosomes, on the other hand, are smaller (50–150 nm)
and are generated within cytoplasmic multivesicular bodies (MVBs) before being
secreted to the extracellular space through subsequent fusion of MVBs with the
plasma membrane [11, 15].
In many neurodegenerative disorders, EVs derived from nerve cells have been
proposed to be responsible for spreading neurotoxins to normal cells, accelerating
disease progression [16–20]. In the diseased cell, misregulated proteins serve as
‘templates’ for subsequent protein oligomerization, generating insoluble toxic
aggregates. Such aggregates are then either degraded by lysosomes using a ‘self-
clearance’ mechanism, or incorporated into MVBs and/or the plasma membrane
facilitating subsequent release into the extracellular space [21]. EV-loaded biomol-
ecules can then be transmitted to recipient cells primarily by endocytosis but also by
endosomal fusion of the EV membrane with cell’s plasma membrane [22]. For
example, exosomes facilitate the intercellular delivery of amyloid beta (Aβ) pep-
tides in Alzheimer’s disease, leading to plaque formation in the recipient cells
[19, 20]. A similar trend of EV-mediated or free protein spreading in a ‘prion-like’
manner is observed in Parkinson’s disease (PD). Specifically, studies with mice have
demonstrated that grafted cells containing aggregated α-synuclein can transfer
these protein aggregates to healthy brain tissue [23].
As the contents of EVs reflect the physiological status of the original cell, recent
studies have begun to evaluate the possibility of using these structures as bio-
markers with which to gauge the onset and progression of a diverse range of
neurodegenerative diseases. Issues remain with identifying tissue specificity and
cell type of origin for pathogenic EVs found in body fluids. However, convenient
sampling and improved understanding of internal cargo molecules’ function has led
to EV’s being seen as one of the strongest candidate classes for next generation
prognosis/diagnosis screening. As with other degenerative diseases of the central
nervous system (CNS), much recent work on ALS has focused on investigating the
pathological role of EVs in diseased neuromuscular tissue, as well as evaluating their
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applicability in the early diagnosis and further treatment of the disease. In this
review, we will highlight recent research studying the diverse roles of EVs in ALS
progression, diagnosis, and treatment. In addition, we will discuss possible solutions
for unsolved problems in this area and suggest future directions for ALS-EV
research to further our understanding of ALS pathology and help develop advanced
diagnosis and treatment methods using EVs.
2. EVs as dysregulated biomolecule carriers for disease propagation
in ALS
ALS tissues commonly contain cells supporting dysregulated protein aggregates
in their cytoplasm and these structures often exert detrimental effects on cell
viability and function. SOD1 (superoxide dismutase 1) and TDP-43 (transactive
DNA binding protein 43 kDa), encoded by the SOD1 and TARDBP genes respec-
tively, are the most well-studied proteins susceptible to ALS-associated aggregation.
Aggregation of these proteins, in some cases due to destabilizing mutations, are
known to be actively involved in motor neuron degeneration in both familial and
sporadic ALS [1, 24, 25]. The SOD1 enzyme resides in the cytoplasm of normal cells
to regulate oxidative stress by converting free superoxide radicals into molecular
oxygen [2]. There are more than 180 mutations reported in the SOD1 gene, and
oligomerization of the encoded proteins has been shown to cause increased intra-
cellular oxidative stress and anomalous metal binding [2]. However, the pathologic
pathway connecting SOD1 mutation, protein dysregulation, and subsequent
neurodegeneration have yet to be defined in a comprehensive manner [2, 26]. TDP-
43 is a highly conserved nuclear RNA and DNA binding protein, known to be
involved in transcriptomic regulation, primarily by RNA splicing but also by effects
on mRNA transport and stability, effects on microRNA production, and participat-
ing in DNA repair [27–31]. Approximately 97% of ALS patients have abnormally
aggregated TDP-43 in their neurons, even without direct mutation of the TARDBP
gene, leading to ALS proteinopathic characteristics in their pathology [6, 32].
Strikingly, recent ALS studies have demonstrated that abnormally transformed
proteins, such as SOD1 and TDP-43, do not merely impair the cells of origin, but
migrate to neighboring cells by means of extracellular exosome release, resulting in
a spread of their cytotoxic effect to recipient cells [33, 34]. Exosome shuttling has
been shown to be a preferred cellular mechanism for removing intracellular toxic
molecules to the extracellular space [35]. The exosomal loading of cytotoxic protein
aggregates is beneficial to host cells since it minimizes the physiological damage
caused by these structures. Such phenomena could be promoted by the host cell
recognizing an increase in intracellular protein aggregation or impaired lysosomal
autophagy. Interestingly, normal neurons cultured with TDP-43 aggregate-loaded
exosomes induce cytoplasmic redistribution of endogenous TDP-43, leading to an
exacerbation of the disease phenotype in mice [36]. Moreover, proteins packaged in
extracellular vesicles are preferentially taken up by recipient cells and exhibit a
greater detrimental physiological effect compared to free protein release, highlight-
ing a crucial role for EV and plasma membrane tethered proteins in regulating
protein internalization and functional activation [37]. These studies suggest an
important interaction between exogenous TDP-43 transported via extracellular
vesicles and endogenous TDP-43 expressed by the recipient cell. Such interactions
constitute a pre-requisite for ‘prion-like’ seeding followed by cytoplasmic protein
redistribution and offer a potential mechanism for the rapid propagation of disease
phenotypes throughout the motor neuron pool. Indeed, when insoluble TDP-43
aggregates taken from ALS brain were introduced to neuron-like SH-SY5Y cells
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endogenously expressing normal TDP-43, the treatment induced significant
aggregation of TDP-43 in recipient cells in a self-templating manner [38].
Similarly, SOD1 aggregates transferred via exosomes have been shown to work
as self-templating ‘seeds’ in recipient cells, leading to the propagation of a
misfolded protein that persists in culture over multiple passages and population
doublings [34].
Although recent studies have observed intercellular protein transmission via
EVs, their specific roles in neuromuscular pathophysiology are poorly understood.
In particular, how the transfer of abnormal proteins induces subsequent neuronal
damage and a breakdown in their electrophysiological function has yet to be eluci-
dated. Furthermore, by taking into account that ALS exhibits non-neuron autono-
mous characteristics, it is essential to obtain a more comprehensive understanding
of whether and how non-neuronal nerve cells can damage neuromuscular function
via the exosomal transfer pathway. Table 1 provides an overview of the studies
performed so far relating to the role of EVs in propagating ALS pathologies to
neighboring cells and these studies are discussed in more detail throughout
this section.
Among non-neuronal cell types, astrocytes have gained significant interest as
carriers of detrimental protein aggregates in ALS tissues. Secretome analysis of
astrocytic exosomes from SOD1 (G93A) mutant mice were reported to contain
SOD1 aggregates, and the exosomal release of these structures accounted for a
larger proportion of SOD1 transport than free SOD1 release [4, 14]. In addition,
proteomic analysis has revealed that proteins involved in vesicle trafficking are
downregulated in mutant astrocytes, indicating a possible impairment of protein
disposal in ALS astrocytes. Moreover, wild-type mice transplanted with astrocyte
progenitors expressing mutant SOD1 exhibit motor neuron impairment, raising the
reasonable postulation that diseased astrocytes utilize extracellular vesicle-mediated
paracrine communication to deliver pathogenic protein aggregates to motor neu-
rons [4, 14]. Another quantitative proteomic analysis of EVs derived from ALS
nervous tissue showed a relative absence of the microglial marker (CD11b) but
positive expression for the astrocyte marker (GLAST) and the synaptic marker
(SNAP25), indicating that astrocytes and neurons may constitute the major cell
types involved in EV-mediated communication in the CNS [7]. However, as the
main function of microglia in the CNS is immune response regulation under pro-
inflammatory conditions, microglia might also actively secrete EVs within an
immune-active environment to modulate the immune response of other nerve cells.
Since ALS is reported to have autoimmune disease characteristics as well [39, 40],
a pathogenic role for EVs secreted from diseased microglia in ALS tissue could be
another important subject to explore.
Do skeletal muscle cells also secrete EVs for neuronal uptake? The breakdown of
neuromuscular junctions (NMJs; the synapses connecting lower motor neurons
and skeletal muscle fibers) is a critical early indicator of pathological onset in ALS.
However, it remains unclear whether NMJ breakdown occurs due to general ill
health of the motor neuron or some aberrant signaling between these neurons and
their afferent synaptic contacts. If the latter is true, a reasonable hypothesis would
be that ALS progression is affected by paracrine communication between skeletal
muscle and motor neurons. To this point, an interesting study in 2017 described the
involvement of skeletal muscle in EV-based crosstalk in neuromuscular tissues. In
ALS muscle biopsies, noticeable accumulation of MVBs containing exosome-like
vesicles were measured, with significant increases in vesicular protein concentra-
tions reported when compared with controls. In addition to the denser protein
accumulation reported in the EVs, ALS skeletal muscle-derived EVs were shown to
exclusively damage neuronal viability in vitro [4, 14].
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Role of EV Study method Source of EV Significance Unknowns Reference
Dysregulated
protein and
RNA carrier
In vitro study
with astrocytes
and mouse
motor neurons
Directly
differentiated
astrocytes from
fALS
(C9ORF72)
patient-derived
fibroblast
Micro-RNAs in
ALS astrocyte-
derived
extracellular
vesicle (EV)
caused neuronal
network
degeneration
and growth
cone impairment
The role of
C9ORF72 protein
for dysregulated
miRNA
encapsulation in
EV
Varcianna
et al. [41]
In vitro/ex vivo
study for whole
tissue vesicle
isolation
Brain- and
spinal cord
tissue from
NTg and SOD1
mutant mice
Brain-derived
astrocytes and
neurons, but not
microglia, were
the main EV
source in CNS
Detailed cargo
modification
pattern of EVs in
the diseased cells
Silverman
et al. [7]
Clinical
research with
sporadic ALS
patients’ body
fluid for EV
analysis
Venous blood
of sALS
patients
Microvesicles of
ALS patients
were enriched
with potentially
pathological
protein (SOD1,
TDP-43, FUS),
while exosomes
did not show any
protein changes
Contradictory
result with other
(in vitro) studies
that suggested
huge loading of
dysregulated
proteins in
exosomes of ALS
mutant cells
Sproviero
et al. [59]
In vitro study
with ALS
mouse muscle-
derived
exosomes
treated to
primary/iPSC-
derived motor
neurons
Skeletal muscle
cells from
SOD1 mutant
mouse
EVs derived
from ALS
myotubes
encapsulated
H2-AX
(neurotoxin)
which suggests
possible
dissemination of
various
neurotoxic
molecules from
diseased skeletal
muscle to
normal neurons
Is H2-AX a major
neurotoxin in
human ALS
skeletal muscle as
well?
Gall
et al. [60]
In vitro study
using Neuro2a
and primary
neurons to
study the role
of exosomes in
ALS
proteinopathy
Primary
neurons and
Neuro2a cells
from ALS
mouse brain
Exosome
secretion was
beneficial in
neuronal
clearance of
pathological
TDP-43, but also
it might be
responsible for
the propagation
of the toxic
TDP-43
aggregates to the
other cells
Should we inhibit
exosome secretion
to prevent
aggregated TDP-43
propagation or
promote the
secretion for TDP-
43 clearance in
neurons?
Iguchi
et al. [36]
In vitro co-
culture of NSC-
34 with cortical
Mutant DPR
(dipeptide
repeat
proteins)
DPRs can be
transmitted to
neurons and glial
cells with/
Difference
between
propagated DPRs
and other
Westergard
et al. [61]
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Although dysregulated protein transfer is of major interest in ALS-EV research,
the role of transmissible miRNAs in facilitating ALS progression should not be
overlooked. EVs obtained from astrocytes derived from ALS patient post-mortem
tissue (C9ORF72 mutation) have been shown to display a neurotoxic phenotype,
inducing mouse motor neuron degeneration, though fewer EVs were secreted from
diseased astrocytes than normal controls [41]. Dysregulated miR-494-3p was iden-
tified as a main component of the diseased EVs. This astrocyte-specific miRNA is
Role of EV Study method Source of EV Significance Unknowns Reference
neurons and
astrocytes
transfected
NSC-34 cells
without
exosome
involvement
dysregulated
proteins (TDP-43,
SOD1) in terms of
their
neurodegeneration
effect?
In vitro study
using ALS
patient-derived
exosomes and
human glioma
cell line (U251)
CSF from 18
sALS patients
ALS-CSF
incubation with
U251 cells
increased mis-
located TDP-43
in the glioma
cells and induced
their apoptotic
behavior and
macro
autophagy
process
Connection
between
propagated TDP-
43 and autophagy
mechanism in
recipient cells
Zhou et al.
[62]
In vitro study
using primary
neurons and
TDP-43
transfected
HEK cells
ALS post-
mortem lysate,
primary
cortical mouse
neurons and
HEK cells
TDP-43
oligomers were
present in EVs
and showed that
microvesicular
TDP-43 exerts
higher toxicity
than free
TDP-43
EV encapsulating
pathway of
neurotoxic TDP-43
oligomers
Feiler et al.
[37]
In vitro study
with
neuroblastoma
cells with brain
tissue obtained
from ALS/FTD
patients
Neuroblastoma
cells expressing
TDP-43 and
SOD1
Misfolded wild-
type proteins
could traverse
cell-to-cell as a
self-templating
‘seed’ either as
free protein
aggregates or
loaded on the
surface of
exosomes
Which specific
receptors control
the uptake of
misfolded TDP-43/
SOD1 presented on
exosomes?
Nonaka
et al. [38]
In vitro study
analyzing
neurotoxic
effect and
amount of
SOD1 protein
encapsulated in
astrocytic
exosomes
Primary
astrocytes from
mouse
expressing
human mutant
SOD1
Mutant SOD1
astrocytes
released
increased
number of
exosomes, which
were toxic for
motor neurons
Protein factors
which involved in
mutant SOD1
astrocytic exosome
Basso et al.
[26]
Table 1.
Overview of the recent findings regarding roles for extracellular vesicles in ALS disease propagation.
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known to negatively regulate semaphorin-3A expression, which is highly involved
in axonal growth and maintenance [41]. Similarly, exosomes secreted by mouse-
derived motor neuron-like cells (NSC-34) transfected with a human SOD1 mutant
variant were enriched with miR-124. This miRNA was in turn transmissible to the
microglia, where it induced impairment of their phagocytic ability and an increase
in pro-inflammatory gene expression [42]. These results indicate the presence of a
multi-directional intercellular communication network in ALS that is mediated by
miRNAs encapsulated in EVs. Researchers have only begun to scratch the surface of
EV-mediated miRNA transfer in ALS and this area requires more comprehensive
study to fully disentangle the pathologic milieu that exists among the different types
of nerve cells in ALS nervous tissue.
Research investigating EV-mediated ALS pathophysiology is in an incipient
stage, and impressive results in previous studies are still raising a number of impor-
tant questions that must be addressed. For example, it is unclear whether the
beneficial effect of elimination of intracellular toxic proteins outweighs the delete-
rious effects of uptake of those proteins by neighboring cells. Understanding this
point will be critical when designing therapeutic methods to inhibit the propagation
process. Furthermore, to promote extracellular disposal of toxic protein aggregates
while inhibiting their uptake by neighboring cells, we need to fully understand the
interactions between surface proteins on detrimental EVs and those on the plasma
membranes of motor neurons. Alternatively, efforts could be focused on enhancing
lysosomal degradation process over EV-mediated protein disposal in diseased cells,
but it is unclear whether the majority of detrimental contents in their multivesicular
bodies can alternatively be delivered to autophagosomes for degradation. Another
gap in EV-ALS research is a lack of studies focused on analyzing motor neuron-
derived EVs to understand the phenotypic effect of transmitting neuron-originated
proteins to other neurons and/or non-neuronal cells within ALS tissues. As motor
neurons are the main target in ALS pathogenesis, pathogenic proteins are likely to
be enriched in motor neuron-derived EVs and could potentially directly damage glia
and/or NMJ structures, or even directly affect skeletal muscle contractility. We
believe that answering these questions, in addition to better characterizing non-
neuronal EV cargos, should constitute the principle focuses of future studies aimed
at improving our understanding of EV-mediated ALS progression. The results of
such work would doubtlessly provide invaluable insights into ALS pathophysiology
and help identify suitable targets for future therapeutic development.
3. Can EVs serve as reliable biomarkers for ALS?
There is no reliable biomarker established for ALS, neither for confirming dis-
ease onset nor for characterizing disease progression [43]. The lack of a reliable
biomarker for ALS makes the correct prognosis challenging, and even limits diag-
nosis to relatively late stages, after patients recognize their neuromuscular symp-
toms. As the typical life expectancy for ALS patients is approximately 2–5 years
after disease onset, early and accurate diagnosis is crucial not only for developing
early-stage applicable therapies, but for improving quality of life for patients during
their follow-up period. A new detection method should be robust and convenient
for clinical settings, and, critically, have sufficient detection sensitivity, specificity,
and reproducibility to ensure confidence in the result. Meeting all these require-
ments simultaneously is an extremely challenging goal, given the extremely hetero-
geneous nature of the disease. Recent studies are evaluating ALS patient-derived
EVs as potential biomarkers of ALS for prognosis, early diagnosis, and patient
stratification. RNAs collected from patient’s blood or cerebrospinal fluid (CSF;
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often used as a surrogate for nervous tissue sampling) are the main target of
analyses so far and advanced RNA-sequencing techniques are being employed to
analyze deregulated RNAs exclusively in ALS patient-derived EVs. Recently, Otake
et al. reported a new methodology using highly sensitive exoRNA-sequencing for
comprehensive analysis of exosomal mRNAs in patient CSF, to identify abnormally
expressed mRNAs in exosome samples from ALS patients [43]. The technique
identified 543 mRNAs exhibiting statistically different expression patterns com-
pared to normal samples. In particular, this analysis revealed that the gene CUEDC2
was only detected in ALS patient-derived exosomes. As the gene is known to
regulate the ubiquitin-proteasome pathway as part of the inflammatory response,
its abnormal expression is postulated to cause potential neuroinflammation in ALS,
making CUEDC2 mRNA a strong biomarker candidate [43]. Follow-up studies are
necessary to demonstrate a specific causal relationship between exosomal CUEDC2
mRNA presence (rather than free intracellular CUEDC2 expression) and ALS
development. Furthermore, work demonstrating an omnipresence of the same RNA
mis-regulation in EVs from other ALS patients is also required. However, the
described study highlights how exosomal mRNAs could be attractive biomarker
candidates, given their stability within body fluids, as well as the convenience of
sample collection and ease of subsequent data analysis. Efforts to date to character-
ize EV cargos as ALS biomarkers, including those discussed in detail above and
below, are summarized in Table 2.
As non-coding RNAs are also reported to be involved in ALS onset and progres-
sion, miRNAs loaded in EVs represent another candidate biomarker class for ALS
diagnosis. Study of free miRNA for ALS detection has been previously reported.
Microarray analyses were performed on ALS mutant mouse-derived cells and
patient serum, and the results identified the expression of 10–13 dysregulated
miRNAs in diseased samples [44, 45]. In addition to free-miRNA analyses, Saucier
et al. tried identifying ALS-associated miRNA signatures in EVs to discriminate
blood between healthy and ALS individuals. Extensive exosomal RNA analysis
using high-throughput sequencing coupled with droplet digital PCR enabled the
identification of a group of dysregulated miRNAs, including miR-183-5p, miR-9-5p,
miR-338-3p and miR-1246, which were all remarkably downregulated in ALS
patient-derived exosomes [45].
EV-based biomarker studies in ALS have so far given promising results and
strong motivation for follow-up studies to further specify molecular candidates
with higher disease relevancy. However, limited information on the exosomal
RNAs, in terms of the specific signaling pathways they regulate, is currently avail-
able. This lack of understanding makes it difficult to determine the relevance of
each when attempting to define a diagnostic EV-RNA signature for ALS. Also, as
significant difficulty lies in identifying the cellular origin of EVs collected from
body fluids, their practical application in diagnostics could be challenging, espe-
cially if the same miRNAs secreted from different cells of origin reflect different
states of the disease. Furthermore, the RNA profile in different subtypes of EVs,
such as exosomes versus microvesicles, that exist in patient’s body fluids has not yet
been investigated. As such, more comprehensive RNA analysis, using entire EV
populations, might give discordant results to those reported from exosomal RNA
analysis. Additionally, to date there has not been any analysis of when specific
RNAs arise during ALS disease progression and whether certain expression patterns
are indicative of certain stages of the pathology. Such an understanding is crucial in
determining whether expression of certain RNAs can be employed effectively as
diagnostic tools or as methods to chart disease progression. Finally, as hundreds of
exosomal RNAs in ALS patient body fluids have been found to exhibit significant
differences in their expression levels relative to normal controls, clinically
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Role of EV Study method Source
of EV
Significance Unknowns Reference
Biomarker Sequencing
exosomal mRNAs
in CSF
CSF of ALS
patients and
normal
donors
A new methodology
for comprehensive
analysis of
exosomal mRNAs
in human CSF using
newly developed
exoRNA-seq, which
showed potential
applicability to
identify specific
ALS biomarkers
Specificity level
of mRNAs
detected in ALS
exosome using
the technique
Otake
et al. [43]
Clinical study
comparing the
expression of miR-
27a-3p in serum-
derived exosomes
Serum of
ALS patients
and healthy
subjects
The expression of
miR-27a-3p in
patients with ALS
was significantly
downregulated than
that in healthy
human serum
exosomes
Specific role of
miR-27-3p in the
expression of
disease
phenotypes in
ALS
Xu et al.
[63]
Clinical analysis of
miRNA profile in 16
ALS patients
Serum of
ALS patients
and healthy
controls
Distinct miRNA
expression profile
was observed in
ALS patient’s
serum-derived
exosomes compared
to healthy controls
Are ALS-
associated
miRNAs
actually
involved in
post-
transcriptional
regulation of
neurons?
Saucier
et al. [45]
In vitro study with
NSC-34 and N9
microglia to
discover ALS
specific miRNAs
Motor
neuron like
NSC-34 cells
with mSOD1
expression
Increased level of
miR-124 in
circulating
exosomes of NSC-
34 may be used as
potential biomarker
of motor neuron
degeneration in
ALS
miR-124
expression in
other health
state? (false
positive issue)
Pinto
et al. [42]
Therapeutic
agent
In vitro study using
adipose-derived
stem cells and
human SOD1
overexpressing
mouse NSCs
Adipose-
derived
stem cells
Adipose-derived
stem cell exosomes
showed paracrine
effect to SVG
neurons to alleviate
their disease
phenotypes and
mitochondrial
dysfunction in ALS
Major exosomal
cargos that exert
each of
therapeutic
effects on
recipient
neurons
Lee
et al. [48]
In vitro study
assessing efficacy of
stromal cell-derived
exosomes on NSC-
34 cells expressing
hSOD1 mutants
Murine
adipose-
derived
stromal cells
The ASC-derived
exosomes were able
to protect motor
neuron-like NSC-34
(SOD1 mutant)
from oxidative
stress and increase
their viability
Where does the
beneficial effect
of ASC-
exosomes come
from?
Bonafede
et al. [50]
Proteomic profiling
of exosomes
derived from mASC
Murine
adipose-
Proteomic analysis
revealed mASC-
derived exosomes
Exosomal effect
on actual
restoration of
Bonafede
et al. [47]
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applicable diagnosis will be difficult until we better understand the physiological
outcomes of those misregulated RNAs in neuromuscular tissue maintenance and
function. Future research elucidating the expression patterns of EV cargos across
diverse ALS populations at different disease stages, as well as studies of the signal-
ing pathways regulated by EV-RNAs in ALS tissue, are therefore necessary before
the value of these molecules in ALS diagnostic medicine can be fully evaluated.
4. EVs for therapeutic agents in ALS treatment
EVs hold distinct advantages for function as stable biomolecule carriers. Their
lipid bilayers, decorated with transmembrane proteins, protect cargo molecules
from enzymatic degradation in the extracellular space as well as making them
immune-tolerant. Functional transmembrane proteins also promote EV internali-
zation into recipient cells, which naturally occurs through active fusion of EV
membranes with cell’s plasma membranes. This in turn facilitates release of EV
molecular cargo to recipient cell cytoplasms or induces endosome uptake for func-
tional activation [23, 46].
Accordingly, an attractive hypothesis is that therapeutic molecules loaded in
vesicles could be delivered to target cells to subsequently modulate phenotypes in
neurodegenerative disease. In such a model, cargo molecules could encompass pro-
teins and mRNAs, or non-coding RNAs for post-transcriptional protein regulation,
or even specific compounds for sustained activation with avoidance of enzymatic
attack. Research efforts to test this hypothesis are summarized in Table 2 and
discussed in detail below. As very few drug candidates with a proven efficacy for
treating ALS exist, research on ‘drug-loaded EVs’ has not yet begun in earnest.
However, adipose-derived stromal cells and stem cells have shown a capacity to
generate exosomes capable of conferring a therapeutic effect on defective neurons.
Exosomes from murine adipose-derived stromal cells alleviated oxidative stress and
reduced hydrogen peroxide-induced apoptosis in NSC-34 cells overexpressing a
human SOD1 mutant variant [47]. Safe availability and a capacity to migrate to
damaged tissues for their reparative processes make stromal cells good candidates
for EV sources. Although the study demonstrated that stromal cell-derived EVs can
reverse SOD-1 induced cell death, such applications have not yet been specifically
targeted to restore electrophysiological phenotypes in ALS neurons. Consequen-
tially, the applicability of stromal cell-derived EVs may be limited if the specific
cargo molecule responsible for restoring motor neuron function is not identified.
Retaining the remarkable therapeutic potential of stem cells, while avoiding
issues with tumorigenicity, insufficient therapeutic specificity, and substantial cell
loss during treatment, stem cell-derived EVs offer an exciting alternative to direct
stem cell therapy. Indeed, EVs obtained from undifferentiated stem cells have
shown a capacity to alleviate disease phenotypes in ALS mutant neurons. Specifi-
cally, exosomes from adipose-derived stem cells reduced SOD1 aggregation and
Role of EV Study method Source
of EV
Significance Unknowns Reference
with in vitro assay
of exosome
treatment on
NSC-34 cells
derived
stem cells
contain proteins for
cell adhesion and
negatively regulate
cell apoptosis
neuronal
function
Table 2.
Summary of the applications of extracellular vesicles in ALS diagnosis and treatment.
10
Amyotrophic Lateral Sclerosis - Recent Advances and Therapeutic Challenges
rescued normal mitochondrial protein expression in mouse neurons [48]. Another
adipose-derived stem cell study performed proteomic analysis of EVs and found 189
exosomal proteins, mainly involved in regulating cell adhesion and negative regu-
lation of apoptosis. Stress response proteins, such as SOD1, were also included in
these exosomes and were found to replace the enzymatic function of mutant SOD1 in
NSC-34 cells. Additionally, the study reported the presence of ribonuclease RNase 4
in the examined exosomes. This could represent a potential neuroprotective molecule
applicable in ALS, as RNase 4 has been reported to have angiogenic, neuroprotective
properties [49, 50].
The field of EV-mediated therapeutics for ALS treatment is still in its infancy.
However, since glial cells and neural stem cells are responsible for regulating neuron
differentiation, protection, and synaptic function [13, 51–54], EVs derived from
those cells could constitute attractive subcomponents for therapeutic agent devel-
opment. As mentioned above, EVs possess distinct advantages for therapeutic
development, including sustained cargo delivery and avoidance of physiological
degradation. Naturally derived EVs, as well as engineered EVs loaded with optimal
therapeutic materials, therefore represent a powerful candidate for the future of
ALS treatment. However, the following issues should be addressed to facilitate the
practical application of EVs in treating this disease. First, since EVs secreted from
one type of cell usually do not target a specific cell type for cargo delivery, higher
delivery specificity to eliminate potential off-target effects is essential. EV mem-
brane engineering to attach proteins with exclusive affinity to target neuron cell
surfaces could be an attractive approach to consider [55–58], if reliable surface
markers for diseased cells can be defined. Second, a lack of information regarding
the physiological function of specific cargo molecules in glia or stem cell-derived EV
limits their applicability in ALS treatment. As disease phenotypes in ALS are
extremely heterogeneous, investigating the role of each EV-loadable molecule with
more categorized efficacy studies beyond cell viability is also highly required. Pro-
duction scale of EVs is a critical issue for the actual application of this technology in
ALS clinics. Although EV collection technology continues to advance to minimize
EV loss and reduce collection time and cost, most EV experiments are still done in
small-scale benchtop studies. This is not a huge issue during these early stages of
research and development, but will cause a critical problem for scale up and
Figure 1.
Schematic summary of the major role EVs play in ALS propagation, diagnosis, and treatment.
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administration as we move closer to clinical trials and subsequent distribution.
Lastly, cargo molecule purity is another significant issue. Even with a single cell
source, EV cargo composition is likely to be different based on culture conditions,
and may fluctuate due to other unknown factors; especially if cell-derived EVs is
advanced to large-scale production (Figure 1).
5. Conclusions
Current EV research in relation to ALS is weighted toward investigating the
pathogenic role of intercellularly transmissible vesicles, with a particular focus on
dysregulated protein propagation. This is likely due to the fact that SOD1 and TDP-
43 mutant cells are already known to produce neurotoxic protein aggregates, which
makes the hypothesis that their dissemination via EVs contributes to the nature of
irreversible degeneration of neuromuscular tissue in ALS a straightforward one.
Several studies have demonstrated that EVs collected from ALS patient’s body fluids
and from mutant non-neuronal cells can be internalized by healthy cells. Their
capacity to induce neurodegenerative behavior in these cells supports the notion
that these structures contribute to the rapid disease progression characteristic of
ALS. However, the effect of collected EV components in specific ALS disease
phenotypes is currently quite ambiguous, especially for correlating neuromuscular
tissue level abnormalities with defined EV component expression. To address this,
EV-mediated interplay, occurring at the diseased NMJ may be a good potential
target for future investigations. EVs secreted from skeletal muscle and motor neu-
rons are known to contribute significantly to the development of normal synaptic
formation at the NMJ and better understanding how these signaling processes are
disrupted in ALS could significantly improve our understanding of early disease
etiology. Work in these early stages of ALS and EVs has also highlighted the poten-
tial for using EVs as either a biomarker for ALS diagnostics or even a potential
therapeutic agent. Although evidence of a causal relationship between misregulated
EV-RNAs and functional impairments in ALS neurons is currently sparse, notable
differences in ALS EV-RNA expression patterns detected by next generation
sequencing does support their potential as future diagnostic tool. EV’s exogenous
nature and pre-established cellular internalization mechanism also provides sub-
stantial motivation to continue research that applies these vesicles in therapy
development, either as a molecule carrier or as a naturally-derived drug in and of
itself. Further studies addressing the non-specificity of EV delivery and issues with
production scale will raise their status as a potent therapeutic means to combat ALS
in the future.
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